Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2024

Open Access 01-12-2024 | Huntington's Disease | Review

Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms

Authors: Russell G. Wells, Lee E. Neilson, Andrew W. McHill, Amie L. Hiller

Published in: Translational Neurodegeneration | Issue 1/2024

Login to get access

Abstract

Huntington's disease (HD) is a devastating neurodegenerative disorder caused by aggregation of the mutant huntingtin (mHTT) protein, resulting from a CAG repeat expansion in the huntingtin gene HTT. HD is characterized by a variety of debilitating symptoms including involuntary movements, cognitive impairment, and psychiatric disturbances. Despite considerable efforts, effective disease-modifying treatments for HD remain elusive, necessitating exploration of novel therapeutic approaches, including lifestyle modifications that could delay symptom onset and disease progression. Recent studies suggest that time-restricted eating (TRE), a form of intermittent fasting involving daily caloric intake within a limited time window, may hold promise in the treatment of neurodegenerative diseases, including HD. TRE has been shown to improve mitochondrial function, upregulate autophagy, reduce oxidative stress, regulate the sleep–wake cycle, and enhance cognitive function. In this review, we explore the potential therapeutic role of TRE in HD, focusing on its underlying physiological mechanisms. We discuss how TRE might enhance the clearance of mHTT, recover striatal brain-derived neurotrophic factor levels, improve mitochondrial function and stress-response pathways, and synchronize circadian rhythm activity. Understanding these mechanisms is critical for the development of targeted lifestyle interventions to mitigate HD pathology and improve patient outcomes. While the potential benefits of TRE in HD animal models are encouraging, future comprehensive clinical trials will be necessary to evaluate its safety, feasibility, and efficacy in persons with HD.
Literature
1.
Huntington G. On chorea. J Neuropsychiatry Clin Neurosci. 1872;15(1):109–12. CrossRef
2.
MacDonald ME, AMbrose CM, Duyao MP, Datson N. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–83. CrossRef
3.
Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, et al. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2016;87(3):282–8. CrossRefPubMedPubMedCentral
4.
Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington’s disease based on natural history. Mov Disord. 2014;29(11):1335–41. CrossRefPubMed
5.
Swami M, Hendricks AE, Gillis T, Massood T, Mysore J, Myers RH, Wheeler VC. Somatic expansion of the Huntington’s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet. 2009;18(16):3039–47.CrossRefPubMedPubMedCentral
6.
Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, Ennis M, Shelbourne PF. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet. 2003;12(24):3359–67.CrossRefPubMed
7.
Johri A, Calingasan NY, Hennessey TM, Sharma A, Yang L, Wille E, et al. Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington’s disease. Hum Mol Genet. 2012;21(5):1124–37.CrossRefPubMed
8.
9.
Podvin S, Reardon HT, Yin K, Mosier C, Hook V. Multiple clinical features of Huntington’s disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration. J Neurol. 2019;266(3):551–64. CrossRefPubMed
10.
van der Burg JM, Bjorkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol. 2009;8(8):765–74.CrossRefPubMed
11.
Smarr B, Cutler T, Loh DH, Kudo T, Kuljis D, Kriegsfeld L, et al. Circadian dysfunction in the Q175 model of Huntington’s disease: network analysis. J Neurosci Res. 2019;97(12):1606–23. CrossRefPubMedPubMedCentral
12.
Gusella JF, MacDonald ME, Lee JM. Genetic modifiers of Huntington’s disease. Mov Disord. 2014;29(11):1359–65.CrossRefPubMed
13.
Langbehn DR, Hayden MR, Paulsen JS, and the P-HDIotHSG. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;15(2):397–408. CrossRef
14.
Consortium GMoHsDG-H. CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell. 2019;178(4):887–900.e14. CrossRef
15.
Consortium GMoHsDG-H. Identification of genetic factors that modify clinical onset of Huntington’s disease. Cell. 2015;162(3):516–26. CrossRef
16.
Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E, et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci. 2004;101(10):3498–503.PubMedPubMedCentralCrossRef
17.
Trembath MK, Horton ZA, Tippett L, Hogg V, Collins VR, Churchyard A, et al. A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord. 2010;25(10):1444–50. PubMedCrossRef
18.
Anton S, Ezzati A, Witt D, McLaren C, Vial P. The effects of intermittent fasting regimens in middle-age and older adults: current state of evidence. Exp Gerontol. 2021;156:111617. PubMedCrossRef
19.
Hadem IKH, Majaw T, Kharbuli B, Sharma R. Beneficial effects of dietary restriction in aging brain. J Chem Neuroanat. 2019;95:123–33.PubMedCrossRef
20.
Fontana L, Ghezzi L, Cross AH, Piccio L. Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. J Exp Med. 2021;218(2):e20190086.PubMedPubMedCentralCrossRef
21.
Ooi TC, Meramat A, Rajab NF, Shahar S, Ismail IS, Azam AA, Sharif R. Intermittent fasting enhanced the cognitive function in older adults with mild cognitive impairment by inducing biochemical and metabolic changes: A 3-year progressive study. Nutrients. 2020;12(9):2644.PubMedPubMedCentralCrossRef
22.
Zuccato C, Tartari M, Crotti A, Goffredo D, Valenza M, Conti L, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet. 2003;35(1):76–83.PubMedCrossRef
23.
Tousley A, Iuliano M, Weisman E, Sapp E, Richardson H, Vodicka P, et al. Huntingtin associates with the actin cytoskeleton and alpha-actinin isoforms to influence stimulus dependent morphology changes. PLoS ONE. 2019;14(2):e0212337.PubMedPubMedCentralCrossRef
24.
25.
Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G, et al. Pathophysiology of chorea and bradykinesia in Huntington’s disease. Mov Disord. 1999;14(3):398–403.PubMedCrossRef
26.
Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537–48.PubMedCrossRef
27.
Yang H, Yang S, Jing L, Huang L, Chen L, Zhao X, et al. Truncation of mutant huntingtin in knock-in mice demonstrates exon1 huntingtin is a key pathogenic form. Nat Commun. 2020;11(1):2582.PubMedPubMedCentralCrossRef
28.
Lunkes A, Lindenberg KS, Ben-Haïem L, Weber C, Devys D, Landwehrmeyer GB, et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell. 2002;10(2):259–69.PubMedCrossRef
29.
Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem. 2010;285(12):8808–23.PubMedPubMedCentralCrossRef
30.
Consortium Hi. Induced pluripotent stem cells from patients with Huntington’s disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell. 2012;11(2):264–78.CrossRef
31.
Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, et al. Neuronal properties, in vivo effects, and pathology of a Huntington’s disease patient-derived induced pluripotent stem cells. Stem Cells. 2012;30(9):2054–62.PubMedCrossRef
32.
Kaye J, Reisine T, Finkbeiner S. Huntington’s disease iPSC models-using human patient cells to understand the pathology caused by expanded CAG repeats. Fac Rev. 2022;11:16.PubMedPubMedCentralCrossRef
33.
Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington’s disease. Prog Neurobiol. 2007;81(5–6):294–330.PubMedCrossRef
34.
Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P. BDNF prevents NMDA-induced toxicity in models of Huntington’s disease: the effects are genotype specific and adenosine A2A receptor is involved. J Neurochem. 2013;125(2):225–35.PubMedCrossRef
35.
Canals JM, Pineda JR, Torres-Peraza JF, Bosch M, Martín-Ibañez R, Muñoz MT, et al. Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J Neurosci. 2004;24(35):7727–39.PubMedPubMedCentralCrossRef
36.
Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington’s disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708–18.PubMedPubMedCentralCrossRef
37.
Croll SD, Suri C, Compton DL, Simmons MV, Yancopoulos GD, Lindsay RM, et al. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience. 1999;93(4):1491–506.PubMedCrossRef
38.
Miranda-Lourenço C, Ribeiro-Rodrigues L, Fonseca-Gomes J, Tanqueiro SR, Belo RF, Ferreira CB, et al. Challenges of BDNF-based therapies: from common to rare diseases. Pharmacol Res. 2020;162: 105281.PubMedCrossRef
39.
Sims SK, Wilken-Resman B, Smith CJ, Mitchell A, McGonegal L, Sims-Robinson C. Brain-derived neurotrophic factor and nerve growth factor therapeutics for brain injury: the current translational challenges in preclinical and clinical research. Neural Plast. 2022;2022:3889300.PubMedPubMedCentralCrossRef
40.
Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, Warner TT. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000;48(1):72–6.PubMedCrossRef
41.
Ciammola A, Sassone J, Sciacco M, Mencacci NE, Ripolone M, Bizzi C, et al. Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington’s disease. Mov Disord. 2011;26(1):130–7.PubMedCrossRef
42.
Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41(5):646–53.PubMedCrossRef
43.
Jin YN, Johnson GV. The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. J Bioenerg Biomembr. 2010;42(3):199–205.PubMedPubMedCentralCrossRef
44.
Che HV, Metzger S, Portal E, Deyle C, Riess O, Nguyen HP. Localization of sequence variations in PGC-1α influence their modifying effect in Huntington disease. Mol Neurodegener. 2011;6(1):1.PubMedPubMedCentralCrossRef
45.
Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006;127(1):59–69.PubMedCrossRef
46.
Ogilvie AC, Nopoulos PC, Schultz JL. Quantifying the onset of unintended weight loss in Huntington’s disease: a retrospective analysis of Enroll-HD. J Huntingt Dis. 2021;10(4):485–92.CrossRef
47.
Goodman AO, Barker RA. Body composition in premanifest Huntington’s disease reveals lower bone density compared to controls. PLoS Curr. 2011;3:Rrn1214.PubMedPubMedCentralCrossRef
48.
Costa de Miranda R, Di Lorenzo N, Andreoli A, Romano L, De Santis GL, Gualtieri P, De Lorenzo A. Body composition and bone mineral density in Huntington’s disease. Nutrition. 2019;59:145–9.PubMedCrossRef
49.
van der Burg JMM, Weydt P, Landwehrmeyer GB, Aziz NA. Effect of body weight on age at onset in Huntington disease: a Mendelian randomization study. Neurol Genet. 2021;7(4):e603.PubMedPubMedCentralCrossRef
50.
51.
Ho DJ, Calingasan NY, Wille E, Dumont M, Beal MF. Resveratrol protects against peripheral deficits in a mouse model of Huntington’s disease. Exp Neurol. 2010;225(1):74–84.PubMedCrossRef
52.
Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis. 2001;8(3):479–91.PubMedCrossRef
53.
Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD. The CREST-E study of creatine for Huntington disease: a randomized controlled trial. Neurology. 2017;89(6):594–601.PubMedPubMedCentralCrossRef
54.
Demetrius L. Of mice and men. When it comes to studying ageing and the means to slow it down, mice are not just small humans. EMBO Rep. 2005;6(Supp 1):39–44.
55.
Patterson RE, Laughlin GA, LaCroix AZ, Hartman SJ, Natarajan L, Senger CM, et al. Intermittent fasting and human metabolic health. J Acad Nutr Diet. 2015;115(8):1203–12.PubMedPubMedCentralCrossRef
56.
Wang Y, Wu R. The effect of fasting on human metabolism and psychological health. Dis Mark. 2022;2022:5653739.
57.
Liu J, Yi P, Liu F. The effect of early time-restricted eating vs later time-restricted eating on weight loss and metabolic health. J Clin Endocrinol Metab. 2023;108(7):1824–34.PubMedCrossRef
58.
Delahaye LB, Bloomer RJ, Butawan MB, Wyman JM, Hill JL, Lee HW, et al. Time-restricted feeding of a high-fat diet in male C57BL/6 mice reduces adiposity but does not protect against increased systemic inflammation. Appl Physiol Nutr Metab. 2018;43(10):1033–42.PubMedCrossRef
59.
Shimizu H, Hanzawa F, Kim D, Sun S, Laurent T, Umeki M, et al. Delayed first active-phase meal, a breakfast-skipping model, led to increased body weight and shifted the circadian oscillation of the hepatic clock and lipid metabolism-related genes in rats fed a high-fat diet. PLoS ONE. 2018;13(10):e0206669.PubMedPubMedCentralCrossRef
60.
Hutchison AT, Regmi P, Manoogian ENC, Fleischer JG, Wittert GA, Panda S, Heilbronn LK. Time-restricted feeding improves glucose tolerance in men at risk for type 2 diabetes: a randomized crossover trial. Obesity (Silver Spring). 2019;27(5):724–32.PubMedCrossRef
61.
62.
Redman LM, Ravussin E. Caloric restriction in humans: impact on physiological, psychological, and behavioral outcomes. Antioxid Redox Signal. 2011;14(2):275–87.PubMedPubMedCentralCrossRef
63.
Hofer SJ, Carmona-Gutierrez D, Mueller MI, Madeo F. The ups and downs of caloric restriction and fasting: from molecular effects to clinical application. EMBO Mol Med. 2022;14(1):e14418.PubMedCrossRef
64.
Mehrpour M, Esclatine A, Beau I, Codogno P. Overview of macroautophagy regulation in mammalian cells. Cell Res. 2010;20(7):748–62.PubMedCrossRef
65.
Dunn WA Jr. Autophagy and related mechanisms of lysosome-mediated protein degradation. Trends Cell Biol. 1994;4(4):139–43.PubMedCrossRef
66.
Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112(12):1809–20.PubMedPubMedCentralCrossRef
67.
Liang XH, Kleeman LK, Jiang HH, Gordon G, Goldman JE, Berry G, et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J Virol. 1998;72(11):8586–96.PubMedPubMedCentralCrossRef
68.
Levine B. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell. 2005;120(2):159–62.PubMed
69.
Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443(7113):780–6.PubMedCrossRef
70.
Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36(6):585–95.PubMedCrossRef
71.
Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, et al. Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease. Nat Neurosci. 2010;13(5):567–76.PubMedPubMedCentralCrossRef
72.
Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 2015;38(1):26–35.PubMedCrossRef
73.
Ravikumar B, Duden R, Rubinsztein DC. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet. 2002;11(9):1107–17.PubMedCrossRef
74.
Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005;170(7):1101–11.PubMedPubMedCentralCrossRef
75.
Walter C, Clemens LE, Müller AJ, Fallier-Becker P, Proikas-Cezanne T, Riess O, et al. Activation of AMPK-induced autophagy ameliorates Huntington disease pathology in vitro. Neuropharmacology. 2016;108:24–38.PubMedCrossRef
76.
77.
Alirezaei M, Kemball CC, Flynn CT, Wood MR, Whitton JL, Kiosses WB. Short-term fasting induces profound neuronal autophagy. Autophagy. 2010;6(6):702–10.PubMedPubMedCentralCrossRef
78.
Erlangga Z, Ghashang SK, Hamdan I, Melk A, Gutenbrunner C, Nugraha B. The effect of prolonged intermittent fasting on autophagy, inflammasome and senescence genes expressions: an exploratory study in healthy young males. Hum Nutr Metab. 2023;32:200189.CrossRef
79.
Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, et al. Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathol Commun. 2018;6(1):16.PubMedPubMedCentralCrossRef
80.
Marosi K, Mattson MP. BDNF mediates adaptive brain and body responses to energetic challenges. Trends Endocrinol Metab. 2014;25(2):89–98.PubMedCrossRef
81.
Mattson MP, Moehl K, Ghena N, Schmaedick M, Cheng A. Intermittent metabolic switching, neuroplasticity and brain health. Nat Rev Neurosci. 2018;19(2):63–80.PubMedPubMedCentralCrossRef
82.
Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer T, et al. Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate. Elife. 2016;5:e15092.PubMedPubMedCentralCrossRef
83.
Marosi K, Kim SW, Moehl K, Scheibye-Knudsen M, Cheng A, Cutler R, et al. 3-Hydroxybutyrate regulates energy metabolism and induces BDNF expression in cerebral cortical neurons. J Neurochem. 2016;139(5):769–81.CrossRefPubMedPubMedCentral
84.
Zhao Y, Jia M, Chen W, Liu Z. The neuroprotective effects of intermittent fasting on brain aging and neurodegenerative diseases via regulating mitochondrial function. Free Radic Biol Med. 2022;182:206–18.PubMedCrossRef
85.
Duan W, Guo Z, Jiang H, Ware M, Li XJ, Mattson MP. Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci. 2003;100(5):2911–6.PubMedPubMedCentralCrossRef
86.
Li PA, Hou X, Hao S. Mitochondrial biogenesis in neurodegeneration. J Neurosci Res. 2017;95(10):2025–9.PubMedCrossRef
87.
88.
Yuan Y, Cruzat VF, Newsholme P, Cheng J, Chen Y, Lu Y. Regulation of SIRT1 in aging: roles in mitochondrial function and biogenesis. Mech Ageing Dev. 2016;155:10–21.PubMedCrossRef
89.
Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease. Hum Mol Genet. 2010;19(20):3919–35.PubMedPubMedCentralCrossRef
90.
Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, et al. Thermoregulatory and metabolic defects in Huntington’s disease transgenic mice implicate PGC-1alpha in Huntington’s disease neurodegeneration. Cell Metab. 2006;4(5):349–62.PubMedCrossRef
91.
Cheng A, Wan R, Yang JL, Kamimura N, Son TG, Ouyang X, et al. Involvement of PGC-1α in the formation and maintenance of neuronal dendritic spines. Nat Commun. 2012;3:1250.PubMedCrossRef
92.
Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway. Cell Metab. 2013;18(5):649–59.PubMedPubMedCentralCrossRef
93.
94.
Pallàs M, Pizarro JG, Gutierrez-Cuesta J, Crespo-Biel N, Alvira D, Tajes M, et al. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies. Neuroscience. 2008;154(4):1388–97.PubMedCrossRef
95.
Tulino R, Benjamin AC, Jolinon N, Smith DL, Chini EN, Carnemolla A, Bates GP. SIRT1 activity is linked to its brain region-specific phosphorylation and is impaired in Huntington’s disease mice. PLoS ONE. 2016;11(1):e0145425.PubMedPubMedCentralCrossRef
96.
Xu J, Jackson CW, Khoury N, Escobar I, Perez-Pinzon MA. Brain SIRT1 mediates metabolic homeostasis and neuroprotection. Front Endocrinol (Lausanne). 2018;9:702.PubMedCrossRef
97.
Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2011;18(1):159–65.PubMedCrossRef
98.
Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington’s disease through activation of multiple Sirt1 targets. Nat Med. 2011;18(1):153–8.PubMedPubMedCentralCrossRef
99.
Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127(6):1109–22.PubMedCrossRef
100.
Naia L, Rosenstock TR, Oliveira AM, Oliveira-Sousa SI, Caldeira GL, Carmo C, et al. Comparative mitochondrial-based protective effects of resveratrol and nicotinamide in Huntington’s disease models. Mol Neurobiol. 2017;54(7):5385–99. .CrossRefPubMed
101.
St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, et al. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397–408.PubMedCrossRef
102.
Gureev AP, Shaforostova EA, Popov VN. Regulation of mitochondrial biogenesis as a way for active longevity: interaction between the Nrf2 and PGC-1α signaling pathways. Front Genet. 2019;10:435.PubMedPubMedCentralCrossRef
103.
Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39(4):199–218.PubMedCrossRef
104.
Kim EN, Lim JH, Kim MY, Ban TH, Jang IA, Yoon HE, et al. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY). 2018;10(1):83–99.PubMedCrossRef
105.
Neilson LE, Quinn JF, Gray NE. Peripheral blood NRF2 expression as a biomarker in human health and disease. Antioxidants (Basel). 2020;10(1):28.
106.
Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM. An autoregulatory loop controls peroxisome proliferator-activated receptor gamma coactivator 1alpha expression in muscle. Proc Natl Acad Sci. 2003;100(12):7111–6.PubMedPubMedCentralCrossRef
107.
Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, Kaasik A. PGC-1{alpha} and PGC-1{beta} regulate mitochondrial density in neurons. J Biol Chem. 2009;284(32):21379–85.PubMedPubMedCentralCrossRef
108.
Weir HJ, Yao P, Huynh FK, Escoubas CC, Goncalves RL, Burkewitz K, et al. Dietary restriction and AMPK increase lifespan via mitochondrial network and peroxisome remodeling. Cell Metab. 2017;26(6):884-96.e5.PubMedPubMedCentralCrossRef
109.
Zhang H, Zhang W, Yun D, Li L, Zhao W, Li Y, et al. Alternate-day fasting alleviates diabetes-induced glycolipid metabolism disorders: roles of FGF21 and bile acids. J Nutr Biochem. 2020;83:108403.PubMedCrossRef
110.
Liu Z, Dai X, Zhang H, Shi R, Hui Y, Jin X, et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun. 2020;11(1):855.PubMedPubMedCentralCrossRef
111.
Madkour MI, El-Serafi AT, Jahrami HA, Sherif NM, Hassan RE, Awadallah S. Ramadan diurnal intermittent fasting modulates SOD2, TFAM, Nrf2, and sirtuins (SIRT1, SIRT3) gene expressions in subjects with overweight and obesity. Diabetes Res Clin Pract. 2019;155:107801.PubMedCrossRef
112.
Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early time-restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. Cell Metab. 2018;27(6):1212-21.e3.CrossRefPubMedPubMedCentral
113.
Phillips MCL, McManus EJ, Brinkhuis M, Romero-Ferrando B. Time-restricted ketogenic diet in Huntington’s disease: a case study. Front Behav Neurosci. 2022;16:931636.PubMedPubMedCentralCrossRef
114.
Estevez-Fraga C, Tabrizi SJ, Wild EJ. Huntington’s disease clinical trials corner. J Huntingt Dis. 2023;12(2):169–85.CrossRef
115.
Aziz NA, Anguelova GV, Marinus J, Lammers GJ, Roos RA. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington’s disease. Parkinsonism Relat Disord. 2010;16(5):345–50.PubMedCrossRef
116.
Diago EB, Martínez-Horta S, Lasaosa SS, Alebesque AV, Pérez-Pérez J, Kulisevsky J, Del Val JL. Circadian rhythm, cognition, and mood disorders in Huntington’s disease. J Huntingt Dis. 2018;7(2):193–8.CrossRef
117.
Goodman AO, Rogers L, Pilsworth S, McAllister CJ, Shneerson JM, Morton AJ, Barker RA. Asymptomatic sleep abnormalities are a common early feature in patients with Huntington’s disease. Curr Neurol Neurosci Rep. 2011;11(2):211–7.PubMedCrossRef
118.
Fitzgerald ES, Stout JC, Glikmann-Johnston Y, Anderson C, Jackson ML. Sleep, circadian rhythms, and cognitive dysfunction in Huntington’s disease. J Huntingt Dis. 2023;12(3):293–304.CrossRef
119.
Kudo T, Schroeder A, Loh DH, Kuljis D, Jordan MC, Roos KP, Colwell CS. Dysfunctions in circadian behavior and physiology in mouse models of Huntington’s disease. Exp Neurol. 2011;228(1):80–90.PubMedCrossRef
120.
Morton AJ, Wood NI, Hastings MH, Hurelbrink C, Barker RA, Maywood ES. Disintegration of the sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci. 2005;25(1):157–63.PubMedPubMedCentralCrossRef
121.
Loh DH, Kudo T, Truong D, Wu Y, Colwell CS. The Q175 mouse model of Huntington’s disease shows gene dosage- and age-related decline in circadian rhythms of activity and sleep. PLoS ONE. 2013;8(7):e69993.PubMedPubMedCentralCrossRef
122.
123.
124.
Zhang Z, Shui G, Li MD. Time to eat reveals the hierarchy of peripheral clocks. Trends Cell Biol. 2021;31(11):869–72.PubMedCrossRef
125.
126.
Wilkinson MJ, Manoogian ENC, Zadourian A, Lo H, Fakhouri S, Shoghi A, et al. Ten-hour time-restricted eating reduces weight, blood pressure, and atherogenic lipids in patients with metabolic syndrome. Cell Metab. 2020;31(1):92-104.e5.PubMedCrossRef
127.
Gill S, Panda S. A Smartphone App reveals erratic diurnal eating patterns in humans that can be modulated for health benefits. Cell Metab. 2015;22(5):789–98.PubMedPubMedCentralCrossRef
128.
Bartlett DM, Cruickshank TM, Hannan AJ, Eastwood PR, Lazar AS, Ziman MR. Neuroendocrine and neurotrophic signaling in Huntington’s disease: implications for pathogenic mechanisms and treatment strategies. Neurosci Biobehav Rev. 2016;71:444–54.CrossRefPubMed
129.
Mulder CK, Papantoniou C, Gerkema MP, Van Der Zee EA. Neither the SCN nor the adrenals are required for circadian time-place learning in mice. Chronobiol Int. 2014;31(9):1075–92.CrossRefPubMedPubMedCentral
130.
Wang HB, Loh DH, Whittaker DS, Cutler T, Howland D, Colwell CS. Time-restricted feeding improves circadian dysfunction as well as motor symptoms in the Q175 mouse model of Huntington’s disease. Eneuro. 2018;5(1):ENEURO.0431-17.2017.CrossRefPubMedPubMedCentral
131.
Whittaker DS, Loh DH, Wang HB, Tahara Y, Kuljis D, Cutler T, et al. Circadian-based treatment strategy effective in the BACHD mouse model of Huntington’s disease. J Biol Rhythm. 2018;33(5):535–54.CrossRef
132.
Martens CR, Rossman MJ, Mazzo MR, Jankowski LR, Nagy EE, Denman BA, et al. Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults. Geroscience. 2020;42(2):667–86.CrossRefPubMedPubMedCentral
133.
Tinsley GM, Forsse JS, Butler NK, Paoli A, Bane AA, La Bounty PM, et al. Time-restricted feeding in young men performing resistance training: a randomized controlled trial. Eur J Sport Sci. 2017;17(2):200–7.CrossRefPubMed
134.
Welton S, Minty R, O’Driscoll T, Willms H, Poirier D, Madden S, et al. Intermittent fasting and weight loss: systematic review. Can Fam Phys. 2020;66(2):117–25.
135.
Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988;81(4):968–75. CrossRefPubMedPubMedCentral
136.
Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I. Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology. 2009;73(5):385–92. CrossRefPubMedPubMedCentral
137.
Christodoulou CC, Demetriou CA, Philippou E, Papanicolaou EZ. Investigating the dietary intake using the CyFFQ semi-quantitative food frequency questionnaire in Cypriot Huntington’s disease patients. Nutrients. 2023;15(5):1136.PubMedPubMedCentralCrossRef
138.
139.
Jodeiri Farshbaf M, Ghaedi K. Huntington’s disease and mitochondria. Neurotox Res. 2017;32(3):518–29. CrossRefPubMed
140.
Goyal MS, Vlassenko AG, Blazey TM, Su Y, Couture LE, Durbin TJ, et al. Loss of brain aerobic glycolysis in normal human aging. Cell Metab. 2017;26(2):353-60.e3.CrossRefPubMedPubMedCentral
141.
Christodoulou CC, Demetriou CA, Zamba-Papanicolaou E. Dietary intake, mediterranean diet adherence and caloric intake in Huntington’s disease: a review. Nutrients. 2020;12(10):2946. CrossRefPubMedPubMedCentral
142.
Martinez-Gonzalez MA, Martin-Calvo N. Mediterranean diet and life expectancy; beyond olive oil, fruits, and vegetables. Curr Opin Clin Nutr Metab Care. 2016;19(6):401–7. CrossRefPubMedPubMedCentral
143.
Wasser CI, Mercieca EC, Kong G, Hannan AJ, McKeown SJ, Glikmann-Johnston Y, et al. Gut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance and clinical outcomes. Brain Commun. 2020;2(2):fcaa110. CrossRefPubMedPubMedCentral
144.
Kong G, Ellul S, Narayana VK, Kanojia K, Ha HTT, Li S, et al. An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington’s disease. Neurobiol Dis. 2021;148:105199. CrossRefPubMed
145.
Martínez Leo EE, Segura Campos MR. Effect of ultra-processed diet on gut microbiota and thus its role in neurodegenerative diseases. Nutrition. 2020;71:110609. CrossRefPubMed
146.
Burtscher J, Pepe G, Maharjan N, Riguet N, Di Pardo A, Maglione V, et al. Sphingolipids and impaired hypoxic stress responses in Huntington disease. Prog Lipid Res. 2023;90:101224. CrossRefPubMed
147.
Brotherton A, Campos L, Rowell A, Zoia V, Simpson SA, Rae D. Nutritional management of individuals with Huntington’s disease: nutritional guidelines. Neurodegener Dis Manag. 2012;2(1):33–43. CrossRef
Metadata
Title
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms
Authors
Russell G. Wells
Lee E. Neilson
Andrew W. McHill
Amie L. Hiller
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2024
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-024-00406-z

Other articles of this Issue 1/2024

Translational Neurodegeneration 1/2024 Go to the issue

Review

Focusing on mitochondria in the brain: from biology to therapeutics

Letter

Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics

Letter

Whole-brain dopamine transporter binding pattern predicts survival in multiple system atrophy

Review

Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer’s disease

Research

α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes

Research

Nanotechnology for microglial targeting and inhibition of neuroinflammation underlying Alzheimer’s pathology